Summit Therapeutics PLC 10-K filed Feb 23, 2026

Modified · Company Overview

The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF (as defined in Part I, Item I Business, Company Overview, Ivonescimab) compound into a single molecule. On December 5, 2022, the Company entered into a Collaboration and License Agreement (the “License Agreement”) with Akeso, Inc. and its affiliates (collectively, “Akeso”) pursuant to which the Company has in-licensed intellectual property rights related to ivonescimab (as amended, the “License Agreement”). Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan. The License Agreement and transaction closed in January 2023 following customary waiting periods. On June 3, 2024, the Company entered into an amendment to the License AgreementSecond Amendment with Akeso to expand its territories covered under the License Agreement to also include the Latin America, Middle Eastincluding Mexico and Africa regions (collectively, all countries in Central America and as expandedSouth America, the "Licensed Territory")Middle East and Africa. The Company’s operations are focused on the development of ivonescimab and other future activities, as the Company determines.